Nelarabine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nelarabine" in English language version.

refsWebsite

Global rank English rank

447^th place

338^th place

4^th place

4^th place

3,984^th place

2,622^nd place

1legislation.gov.au

6,658^th place

4,027^th place

68^th place

117^th place

1guidetopharmacology.org

low place

low place

2^nd place

2^nd place

1semanticscholar.org

11^th place

8^th place

1web.archive.org

1^st place

1^st place

doi.org

Cohen MH, Johnson JR, Justice R, Pazdur R (June 2008). "FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma". The Oncologist. 13 (6): 709–14. doi:10.1634/theoncologist.2006-0017. PMID 18586926. S2CID 23463537.

europa.eu

ema.europa.eu

"Atriance EPAR". European Medicines Agency (EMA). 20 September 2007. Retrieved 4 December 2020.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

fda.gov

"Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.

guidetopharmacology.org

"Nelarabine". Guide to Pharmacology. IUPHAR/BPS. Retrieved 21 August 2015.

legislation.gov.au

"Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024". Federal Register of Legislation. 30 May 2024. Retrieved 10 June 2024.

nih.gov

dailymed.nlm.nih.gov

"Arranon- nelarabine injection". DailyMed. 11 June 2020. Retrieved 4 December 2020.

pubmed.ncbi.nlm.nih.gov

Cohen MH, Johnson JR, Justice R, Pazdur R (June 2008). "FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma". The Oncologist. 13 (6): 709–14. doi:10.1634/theoncologist.2006-0017. PMID 18586926. S2CID 23463537.

semanticscholar.org

api.semanticscholar.org

Cohen MH, Johnson JR, Justice R, Pazdur R (June 2008). "FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma". The Oncologist. 13 (6): 709–14. doi:10.1634/theoncologist.2006-0017. PMID 18586926. S2CID 23463537.

tga.gov.au

"Nelarabine-Reach". Therapeutic Goods Administration (TGA). 5 June 2024. Retrieved 17 June 2024.

web.archive.org

"Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.